{"entity":{"id":"medicare-negotiation-2027-cancer-drugs","kind":"term","name":"Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib","aka":["IPAY 2027","second cycle of Medicare drug price negotiation","Xtandi maximum fair price","Pomalyst maximum fair price","Ibrance maximum fair price","Calquence maximum fair price"],"tldr":"Of the fifteen drugs whose Medicare-negotiated prices start on 1 January 2027, four are cancer medicines: Xtandi (enzalutamide), Pomalyst (pomalidomide), Ibrance (palbociclib) and Calquence (acalabrutinib).","summary":"United States, Medicare Drug Price Negotiation Program, second cycle. CMS's data file of 2 November 2026 lists fifteen selected drugs for initial price applicability year 2027, with maximum fair prices effective 1 January 2027. The four cancer medicines and their single maximum fair price per 30-day equivalent supply, as the file gives them:\n\n- Xtandi (enzalutamide): $7,004.00\n- Pomalyst (pomalidomide): $8,650.00\n- Ibrance (palbociclib): $7,871.00\n- Calquence (acalabrutinib): $8,600.00","asOf":"2026-11-04","links":[{"label":"CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP)","url":"https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip"},{"label":"CMS: Medicare Drug Price Negotiation Program","url":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program"}],"tags":["law","us"],"related":["medicare-negotiation-2026-cancer-drug","medicare-negotiation-2028-cancer-drugs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["enzalutamide","pomalidomide","palbociclib","acalabrutinib"],"companies":[],"institutions":[],"pathways":[],"terms":["inflation-reduction-act"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Figures copied from the CMS CSV dated 2 November 2026 (rows dated 25 November 2025, type 'New IPAY')."],"category":"Regulation & policy"},"route":"/terms/medicare-negotiation-2027-cancer-drugs/","neighbours":{"term":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"medicare-negotiation-2028-cancer-drugs","kind":"term","name":"Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib","route":"/terms/medicare-negotiation-2028-cancer-drugs/"},{"id":"medicare-negotiation-2026-cancer-drug","kind":"term","name":"Medicare negotiated price for ibrutinib (Imbruvica), first cycle","route":"/terms/medicare-negotiation-2026-cancer-drug/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}